Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.
Neuren Pharmaceuticals has secured Health Canada approval for its Clinical Trial Application for the Koala Phase 3 trial of NNZ-2591 in children aged 3 to 12 with Phelan-McDermid syndrome, allowing Canadian sites to be added to what is the first-ever Phase 3 study in this rare disorder. The trial, which already has US FDA IND clearance, is now enrolling at two activated sites in the United States on both coasts, and the expanded North American footprint marks a significant operational step in advancing NNZ-2591 through late-stage development, potentially strengthening Neuren’s position in the rare paediatric neurodevelopmental disease market and offering new hope to patients and families facing limited treatment options.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$23.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing new drug therapies for serious neurological and neurodevelopmental disorders that emerge in early childhood and currently have no or limited approved treatment options. Its lead commercialised products, DAYBUE and DAYBUE STIX (trofinetide), are approved in the United States for the treatment of Rett syndrome under an exclusive worldwide licence with Acadia Pharmaceuticals, while its second drug candidate, NNZ-2591, is being developed for multiple rare neurodevelopmental disorders including Phelan-McDermid, Pitt Hopkins and Angelman syndromes, all of which have received orphan drug designation in the US and EU.
YTD Price Performance: 56.72%
Average Trading Volume: 379,950
Technical Sentiment Signal: Buy
Current Market Cap: A$2.48B
See more insights into NEU stock on TipRanks’ Stock Analysis page.